醋酸氯芬酸:对其在疼痛和风湿病管理中的使用的重新评价。

文章的细节

引用

杜利M,斯宾塞CM,邓恩CJ

醋酸氯芬酸:对其在疼痛和风湿病管理中的使用的重新评价。

药。2001;61(9):1351 - 78。

PubMed ID
11511027 (在PubMed
]
摘要

乙酰氯芬酸是一种口服苯乙酸衍生物,对多种炎症介质有作用。通过它的镇痛和抗炎特性,醋酸氯芬酸在各种疼痛情况下提供症状缓解。在膝骨关节炎患者中,该药减轻疼痛,减轻疾病严重程度,并改善膝关节功能,其程度与双氯芬酸、吡罗昔康和萘普生相似。醋酸氯芬酸可减轻类风湿性关节炎患者的关节炎症、疼痛强度和晨僵持续时间,对这些患者的疗效与酮洛芬、双氯芬酸、吲哚美辛和替诺昔康相似。强直性脊柱炎患者服用醋酸氯芬酸后,晨僵的持续时间和疼痛强度减少,脊柱活动能力改善,改善效果与服用吲哚美辛、萘普生或替诺昔康类似。醋酸氯芬酸对其他疼痛情况也有效(如牙科和妇科)。与其他非甾体抗炎药相比,醋酸氯芬酸对软骨基质合成有刺激作用。醋酸氯芬酸耐受性良好,大多数不良事件轻微和可逆,主要影响胃肠道系统。虽然在个别临床试验中,醋酸氯芬酸的胃肠道不良事件发生率与比较品非甾体抗炎药相似,但因这些事件而导致的停药率在醋酸氯芬酸组明显低于酮洛芬和替诺昔康组。通过对10142例患者与双氯芬酸缓释患者的非随机比较,对3574例患者与双氯芬酸、萘普生、吡罗西康、吲哚美辛、替诺昔康或酮洛芬的13例比较的meta分析,以及与142776例患者的10种其他非甾体抗炎药的初步细节比较,表明该药的整体和/或胃肠道耐受性优于其他非甾体抗炎药。 Further analysis of the above meta-analytical data has indicated that costs incurred as a result of adverse event management are lower with aceclofenac than with a range of comparator NSAIDs. CONCLUSIONS: Trials of 2 to 6 months' duration have shown aceclofenac to be an effective agent in the management of pain and rheumatic disease. Data from in vitro studies indicate properties of particular interest with respect to cartilage matrix effects and selectivity for cyclo-oxygenase-2. Aceclofenac is well tolerated, with encouraging reports of improved general and GI tolerability relative to other NSAIDs from a meta-analysis of double-blind trials and from large nonblind studies.

引用本文的药库数据

药物